Author

Susan Quinn

Observed names: S. Quinn, Susan E. Quinn

Institution: Pfizer (United States)

Observed institutions: University of Southern California, Mayo Clinic, Memorial Sloan Kettering Cancer Center, The University of Texas at San Antonio Health Science Center, Pfizer (United States), University of Washington, Institut Gustave Roussy, Yale Cancer Center, Massachusetts General Hospital, Hôpital Paul-Brousse, Wyeth

OpenAlex ID: A5041247232

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

2010 · Lecia V. Sequist, Benjamin Besse, et al. · Journal of Clinical Oncology · 429

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

2009 · Kwok-K. Wong, Paula M. Fracasso, et al. · Clinical Cancer Research · 301

Phase I Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

2006 · Charles Erlichman, Manuel Hidalgo, et al. · Journal of Clinical Oncology · 148

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

2012 · A.R. Abdul Razak, D. Soulières, et al. · Annals of Oncology · 104

Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer

2019 · Jesús Corral, Tony S Mok, et al. · Future Oncology · 37

Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC)

2004 · S. Tejpar, E. Van Cutsem, et al. · Journal of Clinical Oncology · 31

Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer

2008 · Gunnar Folprecht, Josep Tabernero, et al. · Clinical Cancer Research · 26

203 POSTER Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer

2008 · B. Besse, K.D. Eaton, et al. · European Journal of Cancer Supplements · 15

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers

2017 · Helena A. Yu, Myung-Ju Ahn, et al. · Lung Cancer · 10

Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer

2019 · Weiwei Tan, Nagdeep Giri, et al. · Investigational New Drugs · 6

MA26.11 Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC

2018 · T. Mok, K. Nakagawa, et al. · Journal of Thoracic Oncology · 6

Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial.

2013 · Marie-Lise Audet, Ghassan Allo, et al. · Journal of Clinical Oncology · 6

Potential Predictive Markers of Efficacy of Dacomitinib in Patients with Recurrent/Metastatic Scchn from a Phase 2 Trial

2013 · D. Soulieres, G. Allo, et al. · Annals of Oncology · 1

Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

2011 · Lillian L. Siu, Ghassan Allo, et al. · Molecular Cancer Therapeutics

Works count: 14

Citation count: 1,120

H-index: 9

I10-index: 9